Effect of Probiotics on Appetite Regulation in Adults With Overweight/Obesity

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Healthy, Overweight (BMI > 25), Overweight , Obesity, Male, Female, Adults, Satiety and Food Intake, Gut Microbiota Modulation

In brief

The goal of this 16-week randomised, placebo-controlled parallel study is to investigate the effect of a newly formed probiotic supplement on satiety and gut microbiota composition in healthy men and women with overweight or obesity form 20-70 years old. The main question it aims to answer is: Does the probiotic supplement increase feelings of satiety and alter gut microbiota composition? Participants will: * Receive a daily dose of 6 g probiotic supplement (packed in sachets of 3 g) or placebo for 16 weeks. * Visit the research unit 3 times at baseline, week 8 and week 16 of the intervention for blood draws and delivering fecal samples. * Keep a study diary to report deviations from their daily habits and fill in food questionnaires.

Key facts

Study ID

NCT07715955

Run by

Maastricht University Medical Center

People needed

98

Starts

2026-03-18

Expected to finish

2029-08-18

Last updated by the study team

2026-07-21

Who can join

Age: 20 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women, aged between 20-70 years
• BMI ³ 25 kg/m2
• Stable body weight (weight gain or loss < 3 kg in the past three months)
• Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
• No difficult venipuncture as evidenced during the screening visit

You may not qualify if…

• Diabetic patients (type 1 and type 2)
• Abuse of drugs
• More than 2 units alcoholic consumptions per day for women and 3 for men
• Use of products or dietary supplements known to interfere with the main outcomes 3 months prior to the start of the study as judged by the principal investigators
• Gastrointestinal disease (including IBD and IBS)
• Use of an investigational product within another biomedical intervention trial within the previous 1-month
• Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, autoimmune disease and rheumatoid arthritis
• Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
• use of lipid- and glucose lowering medication, corticosteroid use
• Psychiatric diagnoses including clinical depression
• Intolerances or dietary habits that might interfere with the study (i.e. lactose intolerance or veganism)
• pregnancy
• smoking, vaping
• use of antibiotics up to 3 months prior to the study

Where it is running

• Maastricht University, Department of Nutrition and Movement Sciences — Maastricht, Limburg, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.